KR102596577B1 - 생물학적 샘플로부터 미세소포체를 단리시키고 핵산을 추출하는 방법 - Google Patents
생물학적 샘플로부터 미세소포체를 단리시키고 핵산을 추출하는 방법 Download PDFInfo
- Publication number
- KR102596577B1 KR102596577B1 KR1020227023873A KR20227023873A KR102596577B1 KR 102596577 B1 KR102596577 B1 KR 102596577B1 KR 1020227023873 A KR1020227023873 A KR 1020227023873A KR 20227023873 A KR20227023873 A KR 20227023873A KR 102596577 B1 KR102596577 B1 KR 102596577B1
- Authority
- KR
- South Korea
- Prior art keywords
- dna
- rna
- capture surface
- biological sample
- microvesicles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 170
- 239000012472 biological sample Substances 0.000 title claims abstract description 85
- 108020004707 nucleic acids Proteins 0.000 title abstract description 160
- 102000039446 nucleic acids Human genes 0.000 title abstract description 160
- 150000007523 nucleic acids Chemical class 0.000 title abstract description 160
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 92
- 239000000523 sample Substances 0.000 claims description 57
- 239000003153 chemical reaction reagent Substances 0.000 claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 238000005119 centrifugation Methods 0.000 claims description 24
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 20
- 238000001914 filtration Methods 0.000 claims description 19
- 238000004090 dissolution Methods 0.000 claims description 18
- 239000011324 bead Substances 0.000 claims description 16
- 210000002700 urine Anatomy 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 230000027455 binding Effects 0.000 claims description 10
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 10
- 150000001450 anions Chemical class 0.000 claims description 9
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 9
- 230000009089 cytolysis Effects 0.000 claims description 8
- 230000003750 conditioning effect Effects 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 4
- 239000012228 culture supernatant Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 3
- 230000001143 conditioned effect Effects 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 2
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 239000011574 phosphorus Substances 0.000 claims 2
- 108020004414 DNA Proteins 0.000 description 186
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 119
- 239000012528 membrane Substances 0.000 description 91
- 238000002955 isolation Methods 0.000 description 62
- 238000000605 extraction Methods 0.000 description 52
- 238000007399 DNA isolation Methods 0.000 description 48
- 210000002381 plasma Anatomy 0.000 description 45
- 238000002123 RNA extraction Methods 0.000 description 43
- 239000002245 particle Substances 0.000 description 41
- 230000000694 effects Effects 0.000 description 31
- 108090000623 proteins and genes Proteins 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 25
- 239000008346 aqueous phase Substances 0.000 description 24
- 238000003556 assay Methods 0.000 description 18
- 238000001514 detection method Methods 0.000 description 17
- 239000012530 fluid Substances 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- 239000000090 biomarker Substances 0.000 description 16
- 238000011068 loading method Methods 0.000 description 16
- 108020004999 messenger RNA Proteins 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000004448 titration Methods 0.000 description 16
- 108700011259 MicroRNAs Proteins 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 239000002679 microRNA Substances 0.000 description 15
- 230000035772 mutation Effects 0.000 description 15
- -1 DNA Chemical class 0.000 description 13
- 210000001124 body fluid Anatomy 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000005191 phase separation Methods 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 238000000108 ultra-filtration Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000003161 ribonuclease inhibitor Substances 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 239000011148 porous material Substances 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 238000007400 DNA extraction Methods 0.000 description 7
- 238000011529 RT qPCR Methods 0.000 description 7
- 239000012160 loading buffer Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000013017 sartobind Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000005199 ultracentrifugation Methods 0.000 description 7
- 239000011534 wash buffer Substances 0.000 description 7
- 108010067770 Endopeptidase K Proteins 0.000 description 6
- 102000006382 Ribonucleases Human genes 0.000 description 6
- 108010083644 Ribonucleases Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 210000001808 exosome Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 108020004635 Complementary DNA Proteins 0.000 description 5
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- 102100039540 Exocyst complex component 7 Human genes 0.000 description 5
- 101000813489 Homo sapiens Exocyst complex component 7 Proteins 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004695 Polyether sulfone Substances 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000010804 cDNA synthesis Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 229920006393 polyether sulfone Polymers 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 241001534160 Escherichia virus Qbeta Species 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010047956 Nucleosomes Proteins 0.000 description 4
- 108020004566 Transfer RNA Proteins 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 238000007481 next generation sequencing Methods 0.000 description 4
- 210000001623 nucleosome Anatomy 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091032955 Bacterial small RNA Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 3
- 241000713887 Human endogenous retrovirus Species 0.000 description 3
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 150000001412 amines Chemical group 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000034303 cell budding Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000012869 ethanol precipitation Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical group NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 108020004418 ribosomal RNA Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000004055 small Interfering RNA Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- RSGFPIWWSCWCFJ-VAXZQHAWSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O RSGFPIWWSCWCFJ-VAXZQHAWSA-N 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 239000007989 BIS-Tris Propane buffer Substances 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 210000002726 cyst fluid Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001085 differential centrifugation Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000011143 downstream manufacturing Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 238000002270 exclusion chromatography Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000004910 pleural fluid Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004451 qualitative analysis Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001138 tear Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- GUQQBLRVXOUDTN-XOHPMCGNSA-N 3-[dimethyl-[3-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 GUQQBLRVXOUDTN-XOHPMCGNSA-N 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108091007413 Extracellular RNA Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 238000012369 In process control Methods 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000714210 Leviviridae Species 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 241001538234 Nala Species 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 108091030084 RNA-OUT Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 1
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000002583 cell-derived microparticle Anatomy 0.000 description 1
- 108091092259 cell-free RNA Proteins 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 108091092240 circulating cell-free DNA Proteins 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000001909 effect on DNA Effects 0.000 description 1
- 230000002681 effect on RNA Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000010965 in-process control Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003014 ion exchange membrane Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- ZIYVHBGGAOATLY-UHFFFAOYSA-N methylmalonic acid Chemical compound OC(=O)C(C)C(O)=O ZIYVHBGGAOATLY-UHFFFAOYSA-N 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 229920000344 molecularly imprinted polymer Polymers 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- CGVLVOOFCGWBCS-RGDJUOJXSA-N n-octyl β-d-thioglucopyranoside Chemical compound CCCCCCCCS[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CGVLVOOFCGWBCS-RGDJUOJXSA-N 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000000710 polymer precipitation Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000012799 strong cation exchange Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
- C12Q2563/149—Particles, e.g. beads
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Tires In General (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462022538P | 2014-07-09 | 2014-07-09 | |
| US62/022,538 | 2014-07-09 | ||
| US201462079763P | 2014-11-14 | 2014-11-14 | |
| US62/079,763 | 2014-11-14 | ||
| US201562166890P | 2015-05-27 | 2015-05-27 | |
| US62/166,890 | 2015-05-27 | ||
| PCT/US2015/039760 WO2016007755A1 (en) | 2014-07-09 | 2015-07-09 | Methods for isolating microvesicles and extracting nucleic acids from biological samples |
| KR1020177003611A KR102421185B1 (ko) | 2014-07-09 | 2015-07-09 | 생물학적 샘플로부터 미세소포체를 단리시키고 핵산을 추출하는 방법 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177003611A Division KR102421185B1 (ko) | 2014-07-09 | 2015-07-09 | 생물학적 샘플로부터 미세소포체를 단리시키고 핵산을 추출하는 방법 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220105172A KR20220105172A (ko) | 2022-07-26 |
| KR102596577B1 true KR102596577B1 (ko) | 2023-10-30 |
Family
ID=55064901
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227023873A Active KR102596577B1 (ko) | 2014-07-09 | 2015-07-09 | 생물학적 샘플로부터 미세소포체를 단리시키고 핵산을 추출하는 방법 |
| KR1020177003611A Active KR102421185B1 (ko) | 2014-07-09 | 2015-07-09 | 생물학적 샘플로부터 미세소포체를 단리시키고 핵산을 추출하는 방법 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177003611A Active KR102421185B1 (ko) | 2014-07-09 | 2015-07-09 | 생물학적 샘플로부터 미세소포체를 단리시키고 핵산을 추출하는 방법 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10465183B2 (enExample) |
| EP (2) | EP3623792B1 (enExample) |
| JP (2) | JP6759182B2 (enExample) |
| KR (2) | KR102596577B1 (enExample) |
| CN (2) | CN113699143B (enExample) |
| AU (2) | AU2015287763B2 (enExample) |
| CA (2) | CA2954576C (enExample) |
| ES (2) | ES2762677T3 (enExample) |
| IL (2) | IL250000B (enExample) |
| SG (1) | SG11201700146QA (enExample) |
| WO (1) | WO2016007755A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2744589T3 (es) * | 2011-05-11 | 2020-02-25 | Exosome Diagnostics Inc | Extracción de ácido nucleico de materiales biológicos heterogéneos |
| US11268085B2 (en) | 2014-05-27 | 2022-03-08 | Exosome Diagnostics, Inc. | Methods for isolating microvesicles and extracting nucleic acids from biological samples |
| US10465183B2 (en) | 2014-07-09 | 2019-11-05 | Exosome Diagnostics, Inc. | Methods for isolating microvesicles and extracting nucleic acids from biological samples |
| CN105821031A (zh) * | 2016-01-18 | 2016-08-03 | 昆明医科大学 | 一种二氯甲烷法提取dna的原理 |
| US20190093172A1 (en) | 2016-04-15 | 2019-03-28 | Exosome Diagnostics, Inc. | Plasma-based detection of anaplastic lymphoma kinase (alk) nucleic acids and alk fusion transcripts and uses thereof in diagnosis and treatment of cancer |
| WO2017185086A1 (en) | 2016-04-22 | 2017-10-26 | Exosome Diagnostics, Inc. | Devices and methods for in vivo capture of biological samples and nucleic acids therein |
| MX2018013341A (es) | 2016-05-02 | 2019-09-18 | Encodia Inc | Analisis de macromoleculas que emplea la codificacion de acido nucleico. |
| EP3452613B1 (en) | 2016-05-05 | 2021-12-29 | Exosome Diagnostics, Inc. | Profiling microvesicle nucleic acids and uses thereof as signatures in diagnosis of renal transplant rejection |
| EP4079853A1 (en) | 2016-05-13 | 2022-10-26 | Exosome Diagnostics, Inc. | Automated and manual methods for isolation of extracellular vesicles and co-isolation of cell-free dna from biofluids |
| EP3500687A4 (en) | 2016-08-17 | 2020-07-29 | The Regents of the University of California | NEW METHOD BASED ON AN IMMUNOSOND, ALLOWING THE EVALUATION OF AN ORGANIC DAMAGE STATUS BY AN ACELLULAR DNA ASSAY (CFDNA) BASED ON BIOFLUID |
| CA3035881A1 (en) | 2016-09-14 | 2018-03-22 | Toray Industries, Inc. | Method of collecting cell-free dna |
| JP2019535307A (ja) * | 2016-10-21 | 2019-12-12 | エクソサム ダイアグノスティクス，インコーポレイティド | エキソソーム結合型核酸の配列決定および分析 |
| EP3548635B1 (en) | 2016-11-30 | 2021-04-28 | Exosome Diagnostics, Inc. | Methods to detect mutations in plasma using exosomal rna and cell free dna from non-small cell lung cancer patients |
| CN110072994A (zh) * | 2016-12-23 | 2019-07-30 | 埃克波菲尔有限公司 | 用于纯化或分离微泡和外泌体的方法与组合物 |
| WO2018126278A2 (en) | 2017-01-02 | 2018-07-05 | Exosome Diagnostics, Inc. | Methods to distinguish rna and dna in a combined preparation |
| EP3566051A4 (en) * | 2017-01-06 | 2020-11-04 | Mantra Bio, Inc. | SYSTEMS AND PROCEDURES FOR ALGORITHMIC DISCOVERY AND CHARACTERIZATION OF POPULATIONS OF EXTRACELLULAR VESICLES |
| KR101875594B1 (ko) * | 2017-01-13 | 2018-07-06 | ㈜로제타엑소좀 | 금속을 이용한 세포밖 소포체의 분리 방법 |
| GB201706680D0 (en) | 2017-04-27 | 2017-06-14 | Ge Healthcare Uk Ltd | Device and method for sample isolation |
| JP7225121B2 (ja) | 2017-05-17 | 2023-02-20 | エクソサム ダイアグノスティクス，インコーポレイティド | 微小胞核酸および／またはタンパク質、並びに腎移植拒絶反応マーカーとしてのその使用 |
| CN107267440A (zh) * | 2017-06-09 | 2017-10-20 | 李刚 | 适用于外泌体提取的提取试剂及应用及其提取方法 |
| WO2019013991A2 (en) | 2017-07-12 | 2019-01-17 | Illumina, Inc. | METHODS, SYSTEMS AND MATERIALS FOR EXTRACTING NUCLEIC ACIDS |
| US11899024B2 (en) | 2017-07-12 | 2024-02-13 | Exosome Diagnostics, Inc. | Treatment and diagnosis of parkinson's disease using isolated and enriched populations of biofluid-derived extracellular vesicles |
| EP3655531B1 (en) * | 2017-07-18 | 2024-09-04 | Exosome Diagnostics, Inc. | Sequencing of nucleic acids associated with exosomal isolation from patients with glioblastoma multiforme |
| EP3660142A4 (en) * | 2017-07-26 | 2021-05-05 | Rosetta Exosome | METHOD OF ISOLATION OF EXTRACELLULAR VESICLES USING CATIONS |
| CN111386122A (zh) * | 2017-09-20 | 2020-07-07 | 分子听诊器公司 | 用于检测组织状况的方法和系统 |
| EP3704249B1 (en) | 2017-10-31 | 2025-05-21 | Encodia, Inc. | Kits for analysis using nucleic acid encoding and/or label |
| WO2019132688A1 (ru) * | 2017-12-26 | 2019-07-04 | Общество С Ограниченной Ответственностью "Простагност" | Способ и устройство для выделения внеклеточных везикул из биологических жидкостей с помощью каскадной ультрафильтрации |
| WO2019164227A1 (ko) * | 2018-02-20 | 2019-08-29 | 고려대학교 산학협력단 | 엑소좀을 분리하기 위한 다중 컬럼 및 엑소좀 분리 방법 |
| CN112739832B (zh) | 2018-06-06 | 2024-06-04 | 外来体诊断公司 | 用于开发尿液生物标志物和用于检测膀胱癌的方法 |
| EA202190022A1 (ru) | 2018-06-18 | 2021-03-18 | Эксофарм Лимитид | Способы и композиции для очистки или выделения микровезикул и экзосом |
| CN108841777A (zh) * | 2018-06-22 | 2018-11-20 | 北京恩泽康泰生物科技有限公司 | 基于静电吸附的胞外囊泡及其内含物的提取方法及装置 |
| WO2020090859A1 (ja) * | 2018-10-30 | 2020-05-07 | 国立大学法人名古屋大学 | 細胞外小胞を捕捉するために用いられるデバイス、細胞外小胞の保存方法および移送方法 |
| US12258587B2 (en) | 2018-11-20 | 2025-03-25 | Exosome Diagnostics, Inc. | Compositions and methods for internal controls of microvesicle isolations |
| CN114072499B (zh) | 2019-04-30 | 2024-08-06 | Encodia公司 | 用于制备分析物的方法和相关试剂盒 |
| CA3149690A1 (en) * | 2019-08-08 | 2021-02-11 | Biocartis Nv | Novel nucleic acid purification chemistry |
| WO2021055770A2 (en) | 2019-09-18 | 2021-03-25 | Exosome Diagnostics, Inc. | Compositions, methods, and kits for the isolation of extracellular vesicles |
| EP4055186A1 (en) * | 2019-11-04 | 2022-09-14 | Nasasbiotech, S.L. | Method for isolating nucleic acids |
| EP4077660A1 (en) * | 2019-12-16 | 2022-10-26 | QIAGEN GmbH | Method for enriching vesicular rna |
| EP4077659A1 (en) * | 2019-12-16 | 2022-10-26 | QIAGEN GmbH | Enrichment method |
| WO2021215878A1 (ko) * | 2020-04-24 | 2021-10-28 | 고려대학교 산학협력단 | 미세소포체 분리방법 및 미세소포체 분리장치 |
| JP7384278B2 (ja) * | 2020-04-24 | 2023-11-21 | 東洋紡株式会社 | セルロース系イオン交換膜及びその製造方法、エキソソーム精製用のデバイス、並びにエキソソームの精製方法 |
| EP4158065A1 (en) | 2020-05-29 | 2023-04-05 | Exosome Diagnostics, Inc. | Use of microvesicle signature for the diagnosis and treatment of kidney transplant rejection |
| WO2022133159A1 (en) | 2020-12-17 | 2022-06-23 | Nephrosant, Inc. | Kits for stabilization of urine samples |
| WO2022263500A1 (en) * | 2021-06-17 | 2022-12-22 | Qiagen Gmbh | Method for isolating non-vesicular mirna |
| WO2023288130A1 (en) | 2021-07-16 | 2023-01-19 | Exosome Diagnostics, Inc. | Methods of detecting sjögren's syndrome using salivary exosomes |
| DE102021208893B3 (de) | 2021-08-13 | 2022-11-17 | Hahn-Schickard-Gesellschaft für angewandte Forschung e.V. | Isolieren von Analyten unterschiedlicher Analyt-Klassen |
| EP4419911A4 (en) * | 2021-10-28 | 2025-03-05 | 10X Genomics, Inc. | Methods for sample preparation |
| CA3252553A1 (en) | 2022-02-18 | 2023-08-24 | Bio-Techne Corporation | USE OF MICROVESICULAR SIGNATURES IN THE IDENTIFICATION AND TREATMENT OF KIDNEY DISORDERS |
| EP4584397A1 (en) | 2022-09-07 | 2025-07-16 | Exosome Diagnostics, Inc. | Methods of detecting sjögren's syndrome using salivary exosomes |
| CN115960885B (zh) * | 2022-10-09 | 2023-12-12 | 南京诺唯赞生物科技股份有限公司 | 一种提取肝素钠样品中核酸的方法及组合物 |
| KR102784335B1 (ko) * | 2023-02-09 | 2025-03-19 | 순천향대학교 산학협력단 | 세포유리핵산의 고농축화 분리 방법 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014036391A1 (en) * | 2012-08-30 | 2014-03-06 | Exosome Diagnostics, Inc. | Controls for nucleic acid assays |
| US20140093880A1 (en) * | 2012-09-28 | 2014-04-03 | Samsung Electronics Co., Ltd. | Compositions, kits, and methods for isolating vesicles |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935342A (en) | 1986-12-01 | 1990-06-19 | Syngene, Inc. | Method of isolating and purifying nucleic acids from biological samples |
| US5438128A (en) | 1992-02-07 | 1995-08-01 | Millipore Corporation | Method for rapid purifiction of nucleic acids using layered ion-exchange membranes |
| US5639606A (en) | 1993-04-06 | 1997-06-17 | The University Of Rochester | Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction |
| WO1995006652A1 (en) * | 1993-08-30 | 1995-03-09 | Promega Corporation | Nucleic acid purification compositions and methods |
| FR2788780B1 (fr) | 1999-01-27 | 2001-03-30 | Ap Cells Inc | Procede de preparation de vesicules membranaires |
| GB9927320D0 (en) | 1999-11-18 | 2000-01-12 | Chiron Spa | Exosome separation |
| US6812023B1 (en) | 2000-04-27 | 2004-11-02 | Anosys, Inc. | Methods of producing membrane vesicles |
| CA2668818C (en) * | 2006-10-10 | 2018-06-26 | Xenomics, Inc. | Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media |
| ES2936256T3 (es) | 2008-02-01 | 2023-03-15 | Massachusetts Gen Hospital | Uso de microvesículas en el diagnóstico, y pronóstico de enfermedades y afecciones médicas |
| WO2010065765A2 (en) * | 2008-12-04 | 2010-06-10 | Aethlon Medical, Inc. | Affinity capture of circulating biomarkers |
| WO2010141862A2 (en) * | 2009-06-05 | 2010-12-09 | Mayo Foundation For Medical Education And Research | Methods and materials for isolating exosomes |
| WO2011151428A1 (en) | 2010-06-01 | 2011-12-08 | Qiagen Gmbh | Method for isolating and/or purifying nucleic acid(s) |
| EP2591359B1 (en) * | 2010-07-07 | 2017-03-01 | Aethlon Medical Inc | Methods for quantifying exosomes |
| US8945509B2 (en) * | 2010-08-20 | 2015-02-03 | Life Technologies Corporation | Magnetic beads having surface glycoconjugates and use thereof |
| EP2638057B1 (en) * | 2010-11-10 | 2019-03-06 | Exosome Diagnostics, Inc. | Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom |
| US20140004601A1 (en) * | 2010-12-20 | 2014-01-02 | Agency For Science, Technology And Research | Method of purifying exosomes |
| ES2744589T3 (es) | 2011-05-11 | 2020-02-25 | Exosome Diagnostics Inc | Extracción de ácido nucleico de materiales biológicos heterogéneos |
| CN103797131A (zh) * | 2011-06-16 | 2014-05-14 | 卡里斯生命科学卢森堡控股有限责任公司 | 生物标志物组合物和方法 |
| KR20140005688A (ko) * | 2012-07-06 | 2014-01-15 | 삼성전자주식회사 | 사용자 인터페이스 방법 및 장치 |
| MX392552B (es) | 2013-01-03 | 2025-03-11 | Exosome Diagnostics Inc | Métodos para aislar microvesículas. |
| US10465183B2 (en) | 2014-07-09 | 2019-11-05 | Exosome Diagnostics, Inc. | Methods for isolating microvesicles and extracting nucleic acids from biological samples |
-
2015
- 2015-07-09 US US15/325,021 patent/US10465183B2/en active Active
- 2015-07-09 WO PCT/US2015/039760 patent/WO2016007755A1/en not_active Ceased
- 2015-07-09 AU AU2015287763A patent/AU2015287763B2/en active Active
- 2015-07-09 SG SG11201700146QA patent/SG11201700146QA/en unknown
- 2015-07-09 CN CN202110781733.3A patent/CN113699143B/zh active Active
- 2015-07-09 CA CA2954576A patent/CA2954576C/en active Active
- 2015-07-09 ES ES15818561T patent/ES2762677T3/es active Active
- 2015-07-09 CN CN201580049375.XA patent/CN107002075B/zh active Active
- 2015-07-09 ES ES19201765T patent/ES2898254T3/es active Active
- 2015-07-09 KR KR1020227023873A patent/KR102596577B1/ko active Active
- 2015-07-09 KR KR1020177003611A patent/KR102421185B1/ko active Active
- 2015-07-09 EP EP19201765.5A patent/EP3623792B1/en active Active
- 2015-07-09 JP JP2017501235A patent/JP6759182B2/ja active Active
- 2015-07-09 EP EP15818561.1A patent/EP3167062B1/en active Active
- 2015-07-09 CA CA3084920A patent/CA3084920C/en active Active
-
2017
- 2017-01-09 IL IL250000A patent/IL250000B/en active IP Right Grant
-
2019
- 2019-10-17 AU AU2019250221A patent/AU2019250221B2/en active Active
-
2020
- 2020-09-02 JP JP2020147390A patent/JP7128866B2/ja active Active
-
2021
- 2021-01-20 IL IL280307A patent/IL280307B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014036391A1 (en) * | 2012-08-30 | 2014-03-06 | Exosome Diagnostics, Inc. | Controls for nucleic acid assays |
| US20140093880A1 (en) * | 2012-09-28 | 2014-04-03 | Samsung Electronics Co., Ltd. | Compositions, kits, and methods for isolating vesicles |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7128866B2 (ja) | 微小小胞体を単離する方法、および生体試料から核酸を抽出する方法 | |
| JP7354327B2 (ja) | 生体液からの細胞外小胞の単離及びセルフリーｄｎａの同時単離のための自動及び手動方法 | |
| JP6449781B2 (ja) | 微細小胞の単離方法 | |
| US11268085B2 (en) | Methods for isolating microvesicles and extracting nucleic acids from biological samples | |
| CA3022528C (en) | Automated and manual methods for isolation of extracellular vesicles and co-isolation of cell-free dna from biofluids | |
| HK1238676A1 (en) | Methods for isolating microvesicles and extracting nucleic acids from biological samples |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20220711 Application number text: 1020177003611 Filing date: 20170209 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20220725 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230216 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20231011 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20231026 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20231026 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |